Alhamhoom Yahya, Said Ashitha Kakarlapudi, Kumar Avichal, Nanjappa Shivakumar Hagalavadi, Wali Divya, Rahamathulla Mohamed, Farhana Syeda Ayesha, Ahmed Mohammed Muqtader, Shivanandappa Thippeswamy Boreddy
Department of Pharmaceutics, College of Pharmacy, King Khalid University, Al Faraa, Abha 62223, Saudi Arabia.
Department of Pharmaceutics, KLE College of Pharmacy, Rajajinagar, Bengaluru 560010, India.
Polymers (Basel). 2024 Oct 17;16(20):2919. doi: 10.3390/polym16202919.
Loratadine (LOR) is a second-generation antihistamine that exhibits a low and variable oral bioavailability (10-40%) and delayed onset owing to poor solubility and an extensive first-pass effect. Therefore, in light of the clinical need, the main goal of the present study was to develop sublingual fast-dissolving thin films of LOR-citric acid co-amorphous systems (LOR-CAs) with the aim of eliciting a faster onset and improving the bioavailability. We formulated sublingual fast-dissolving thin films of LOR by a film-casting technique using hydrophilic polymers like hydroxypropyl methylcellulose (HPMC E15), polyvinyl pyrrolidone K30 (PVP K30), and hydroxypropyl cellulose EL (HPC-EF) and citric acid as a pH modulator, while glycerin served as a plasticizer. The sublingual fast-dissolving thin films were characterized by FTIR, SEM, DSC, and XRD and evaluated for in vitro dissolution and ex vivo mucoadhesion. The best formulation (F1) developed using HPMC E15 as a polymer, glycerin as a plasticizer, and citric acid as a pH modulator was found to be the optimized formulation as it was smooth, clear, flexible, and displayed good mucoadhesion (11.27 ± 0.418 gm/cm) and uniform thickness (0.25 ± 0.02 mm). The formulation F1 was found to display a significantly shorter DT (30.30 ± 0.6 s) and rapid release of LOR (92.10 ± 2.3% in 60 min) compared to other formulations (ANOVA, < 0.001). The results indicated that the prepared sublingual films are likely to elicit a faster therapeutic effect, avoid first-pass metabolism, and improve the bioavailability.
氯雷他定(LOR)是一种第二代抗组胺药,由于其溶解度差和广泛的首过效应,口服生物利用度较低且变化较大(10 - 40%),起效延迟。因此,鉴于临床需求,本研究的主要目标是开发氯雷他定 - 柠檬酸共无定形系统(LOR - CAs)的舌下速溶薄膜,以实现更快起效并提高生物利用度。我们采用流延技术,使用亲水性聚合物如羟丙基甲基纤维素(HPMC E15)、聚乙烯吡咯烷酮K30(PVP K30)和羟丙基纤维素EL(HPC - EF)以及柠檬酸作为pH调节剂来制备LOR的舌下速溶薄膜,同时甘油用作增塑剂。通过傅里叶变换红外光谱(FTIR)、扫描电子显微镜(SEM)、差示扫描量热法(DSC)和X射线衍射(XRD)对舌下速溶薄膜进行表征,并评估其体外溶出度和体内黏膜黏附性。发现以HPMC E15为聚合物、甘油为增塑剂、柠檬酸为pH调节剂开发的最佳制剂(F1)为优化制剂,因为它光滑、透明、柔韧,具有良好的黏膜黏附性(11.27±0.418 g/cm)和均匀的厚度(0.25±0.02 mm)。与其他制剂相比,制剂F1显示出显著更短的崩解时间(DT,30.30±0.6秒)和LOR的快速释放(60分钟内为92.10±2.3%)(方差分析,P<0.001)。结果表明,所制备的舌下薄膜可能会产生更快的治疗效果,避免首过代谢,并提高生物利用度。